ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents

Marianne Pavel, Juan W. Valle, Barbro Eriksson, Anja Rinke, Martyn Caplin, Jie Chen, Frederico Costa, Jenny Falkerby, Nicola Fazio, Vera Gorbounova, Wouter De Herder, Matthew Kulke, Catherine Lombard-Bohas, Juan O'Connor, Halfdan Sorbye, Rocio Garcia-Carbonero

Research output: Contribution to journalArticle

Abstract

Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild to moderate severity and manageable, novel targeted drugs exhibit a distinct adverse event profile that warrants guidance for appropriate diagnostic and therapeutic management. This is particularly important given the widespread and potentially long-term use of everolimus in a broad spectrum of NETs and of sunitinib in pancreatic NETs. This review will focus on the most relevant toxicities associated with biotherapy and novel targeted drugs and on their management. For each drug class indication, administration and dosing schedule, most frequent adverse events, actions and dose adjustments for adverse events as well as their monitoring are presented. This review further covers the evaluation of treatment effect, patient information, drug interactions, and information on pregnancy.

Original languageEnglish
Pages (from-to)266-280
Number of pages15
JournalNeuroendocrinology
Volume105
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Biological Therapy
Standard of Care
Neuroendocrine Tumors
Guidelines
Pharmaceutical Preparations
Neoplasms
Therapeutics
Sirolimus
Somatostatin
Drug Interactions
Protein-Tyrosine Kinases
Interferons
Appointments and Schedules
Pregnancy

Keywords

  • Dose adjustment
  • Drug interaction
  • Everolimus
  • Interferon-á
  • Patient information
  • Somatostatin analogs
  • Sunitinib
  • Tolerability
  • Toxicity

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Pavel, M., Valle, J. W., Eriksson, B., Rinke, A., Caplin, M., Chen, J., ... Garcia-Carbonero, R. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology, 105(3), 266-280. https://doi.org/10.1159/000471880

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms : Systemic Therapy-Biotherapy and Novel Targeted Agents. / Pavel, Marianne; Valle, Juan W.; Eriksson, Barbro; Rinke, Anja; Caplin, Martyn; Chen, Jie; Costa, Frederico; Falkerby, Jenny; Fazio, Nicola; Gorbounova, Vera; De Herder, Wouter; Kulke, Matthew; Lombard-Bohas, Catherine; O'Connor, Juan; Sorbye, Halfdan; Garcia-Carbonero, Rocio.

In: Neuroendocrinology, Vol. 105, No. 3, 01.09.2017, p. 266-280.

Research output: Contribution to journalArticle

Pavel, M, Valle, JW, Eriksson, B, Rinke, A, Caplin, M, Chen, J, Costa, F, Falkerby, J, Fazio, N, Gorbounova, V, De Herder, W, Kulke, M, Lombard-Bohas, C, O'Connor, J, Sorbye, H & Garcia-Carbonero, R 2017, 'ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents', Neuroendocrinology, vol. 105, no. 3, pp. 266-280. https://doi.org/10.1159/000471880
Pavel, Marianne ; Valle, Juan W. ; Eriksson, Barbro ; Rinke, Anja ; Caplin, Martyn ; Chen, Jie ; Costa, Frederico ; Falkerby, Jenny ; Fazio, Nicola ; Gorbounova, Vera ; De Herder, Wouter ; Kulke, Matthew ; Lombard-Bohas, Catherine ; O'Connor, Juan ; Sorbye, Halfdan ; Garcia-Carbonero, Rocio. / ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms : Systemic Therapy-Biotherapy and Novel Targeted Agents. In: Neuroendocrinology. 2017 ; Vol. 105, No. 3. pp. 266-280.
@article{093e67bbdae5414fa813a710988fee0d,
title = "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents",
abstract = "Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild to moderate severity and manageable, novel targeted drugs exhibit a distinct adverse event profile that warrants guidance for appropriate diagnostic and therapeutic management. This is particularly important given the widespread and potentially long-term use of everolimus in a broad spectrum of NETs and of sunitinib in pancreatic NETs. This review will focus on the most relevant toxicities associated with biotherapy and novel targeted drugs and on their management. For each drug class indication, administration and dosing schedule, most frequent adverse events, actions and dose adjustments for adverse events as well as their monitoring are presented. This review further covers the evaluation of treatment effect, patient information, drug interactions, and information on pregnancy.",
keywords = "Dose adjustment, Drug interaction, Everolimus, Interferon-{\'a}, Patient information, Somatostatin analogs, Sunitinib, Tolerability, Toxicity",
author = "Marianne Pavel and Valle, {Juan W.} and Barbro Eriksson and Anja Rinke and Martyn Caplin and Jie Chen and Frederico Costa and Jenny Falkerby and Nicola Fazio and Vera Gorbounova and {De Herder}, Wouter and Matthew Kulke and Catherine Lombard-Bohas and Juan O'Connor and Halfdan Sorbye and Rocio Garcia-Carbonero",
year = "2017",
month = "9",
day = "1",
doi = "10.1159/000471880",
language = "English",
volume = "105",
pages = "266--280",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms

T2 - Systemic Therapy-Biotherapy and Novel Targeted Agents

AU - Pavel, Marianne

AU - Valle, Juan W.

AU - Eriksson, Barbro

AU - Rinke, Anja

AU - Caplin, Martyn

AU - Chen, Jie

AU - Costa, Frederico

AU - Falkerby, Jenny

AU - Fazio, Nicola

AU - Gorbounova, Vera

AU - De Herder, Wouter

AU - Kulke, Matthew

AU - Lombard-Bohas, Catherine

AU - O'Connor, Juan

AU - Sorbye, Halfdan

AU - Garcia-Carbonero, Rocio

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild to moderate severity and manageable, novel targeted drugs exhibit a distinct adverse event profile that warrants guidance for appropriate diagnostic and therapeutic management. This is particularly important given the widespread and potentially long-term use of everolimus in a broad spectrum of NETs and of sunitinib in pancreatic NETs. This review will focus on the most relevant toxicities associated with biotherapy and novel targeted drugs and on their management. For each drug class indication, administration and dosing schedule, most frequent adverse events, actions and dose adjustments for adverse events as well as their monitoring are presented. This review further covers the evaluation of treatment effect, patient information, drug interactions, and information on pregnancy.

AB - Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild to moderate severity and manageable, novel targeted drugs exhibit a distinct adverse event profile that warrants guidance for appropriate diagnostic and therapeutic management. This is particularly important given the widespread and potentially long-term use of everolimus in a broad spectrum of NETs and of sunitinib in pancreatic NETs. This review will focus on the most relevant toxicities associated with biotherapy and novel targeted drugs and on their management. For each drug class indication, administration and dosing schedule, most frequent adverse events, actions and dose adjustments for adverse events as well as their monitoring are presented. This review further covers the evaluation of treatment effect, patient information, drug interactions, and information on pregnancy.

KW - Dose adjustment

KW - Drug interaction

KW - Everolimus

KW - Interferon-á

KW - Patient information

KW - Somatostatin analogs

KW - Sunitinib

KW - Tolerability

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85016600286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016600286&partnerID=8YFLogxK

U2 - 10.1159/000471880

DO - 10.1159/000471880

M3 - Article

AN - SCOPUS:85016600286

VL - 105

SP - 266

EP - 280

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 3

ER -